Rafael Holdings Appoints New CEO, CFO, and Directors
Ticker: RFL · Form: 8-K · Filed: Aug 8, 2024 · CIK: 1713863
Sentiment: neutral
Topics: management-change, board-of-directors, executive-appointment
Related Tickers: RFL
TL;DR
New CEO & CFO in at Rafael Holdings, Inc. (RFL) - board shakeup.
AI Summary
Rafael Holdings, Inc. announced on August 5, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, David J. Feldman and David M. Miller, and appointed David J. Feldman as Chief Executive Officer and Chief Financial Officer. These changes are effective immediately.
Why It Matters
The appointment of a new CEO and CFO, along with new board members, signals a potential shift in the company's strategic direction and leadership.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- Rafael Holdings, Inc. (company) — Registrant
- David J. Feldman (person) — Newly appointed CEO and CFO, and Director
- David M. Miller (person) — Newly appointed Director
- August 5, 2024 (date) — Effective date of changes
FAQ
Who are the new directors appointed to Rafael Holdings, Inc.'s board?
David J. Feldman and David M. Miller were elected as new directors.
What are the new roles for David J. Feldman?
David J. Feldman has been appointed as Chief Executive Officer and Chief Financial Officer.
When were these changes effective?
The changes reported in this Form 8-K were effective as of August 5, 2024.
What is the principal executive office address for Rafael Holdings, Inc.?
The principal executive offices are located at 520 Broad Street, Newark, New Jersey 07102.
What is the company's fiscal year end?
The company's fiscal year ends on July 31.
Filing Stats: 603 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-08-08 07:44:37
Key Financial Figures
- $0.1 — tered Class B common stock, par value $0.1 per share RFL New York Stock Exchan
Filing Documents
- ea0210862-8k_rafael.htm (8-K) — 28KB
- 0001213900-24-066336.txt ( ) — 195KB
- rfl-20240805.xsd (EX-101.SCH) — 3KB
- rfl-20240805_lab.xml (EX-101.LAB) — 33KB
- rfl-20240805_pre.xml (EX-101.PRE) — 22KB
- ea0210862-8k_rafael_htm.xml (XML) — 3KB
02 Departure of Directors or
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On August 5, 2024, Mark McCamish resigned as director of Rafael Holdings, Inc., effective immediately. (d) On August 5, 2024, Mark N. Stein, MD was elected as a director of Rafael Holdings, Inc. and elected as a member of the Company's Board of Directors Audit, Compensation and Corporate governance committees. Dr. Stein, age 53, has been on staff as a medical oncologist focusing on genitourinary malignancies at Columbia University Irving Medical Center (CUIMC). Dr. Stein is an Associate Professor of Medicine, Director of the Genitourinary Medical Oncology Service and a member of the Developmental Therapeutics program at CUIMC. Dr. Stein completed an Internal Medicine Residency at Montefiore Medical Center from 1998 to 2001 and an Hematology/Oncology Fellowship at Mount Sinai Medical Center from 2001 to 2004. From 2004 until 2018 Dr. Stein worked as a medical oncologist at the Cancer Institute of New Jersey, Rutgers University. Dr. Stein has extensive experience leading early-stage clinical trials with novel therapeutics and has worked with multiple small to mid-size pharmaceutical companies to bring early assets into the clinic. Dr. Stein's academic interests focus on use of immunotherapy for the treatment of prostate and kidney cancer and he has led investigator initiated and industry sponsored studies in this space. Dr. Stein received a Bachelor of Science from Yale University in 1993 and M.D. from New York Medical College in 1998. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RAFAEL HOLDINGS, INC. By: /s/ William Conkling Name: William Conkling Title: Chief Executive Officer Dated: August 8, 2024 2